Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial

2013 ◽  
Vol 27 (4) ◽  
pp. E359-E367 ◽  
Author(s):  
Evaldo Favi ◽  
Gionata Spagnoletti ◽  
Maria P. Salerno ◽  
José A. Pedroso ◽  
Jacopo Romagnoli ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Mycophenolate Mofetil ◽  
Kidney Transplant ◽  
Deceased Donor ◽  
Transplant Recipients ◽  
Single Center ◽  
Kidney Transplant Recipients ◽  
Donor Kidney ◽  
Deceased Donor Kidney ◽  
Deceased Donor Kidney Transplant

scholarly journals Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial

PLoS Medicine ◽  
2021 ◽  
Vol 18 (6) ◽  
pp. e1003668
Author(s):  
Piero Ruggenenti ◽  
Paolo Cravedi ◽  
Eliana Gotti ◽  
Annarita Plati ◽  
Maddalena Marasà ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Kidney Transplant ◽  
Low Dose ◽  
Deceased Donor ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Donor Kidney ◽  
Deceased Donor Kidney ◽  
Deceased Donor Kidney Transplant

Background We compared protection of mycophenolate mofetil (MMF) and azathioprine (AZA) against acute cellular rejection (ACR) and chronic allograft nephropathy (CAN) in kidney transplant recipients on steroid-free, low-dose cyclosporine (CsA) microemulsion maintenance immunosuppression. Methods and findings ATHENA, a pragmatic, prospective, multicenter trial conducted by 6 Italian transplant centers, compared the outcomes of 233 consenting recipients of a first deceased donor kidney transplant induced with low-dose thymoglobulin and basiliximab and randomized to MMF (750 mg twice/day, n = 119) or AZA (75 to 125 mg/day, n = 114) added-on maintenance low-dose CsA microemulsion and 1-week steroid. In patients without acute clinical or subclinical rejections, CsA dose was progressively halved. Primary endpoint was biopsy-proven CAN. Analysis was by intention to treat. Participants were included between June 2007 and July 2012 and followed up to August 2016. Between-group donor and recipient characteristics, donor/recipient mismatches, and follow-up CsA blood levels were similar. During a median (interquartile range (IQR)) follow-up of 47.7 (44.2 to 48.9) months, 29 of 87 biopsied patients on MMF (33.3%) versus 31 of 88 on AZA (35.2%) developed CAN (hazard ratio (HR) [95% confidence interval (CI)]: 1.147 (0.691 to 1.904, p = 0.595). Twenty and 21 patients on MMF versus 34 and 14 on AZA had clinical [HR (95% CI): 0.58 (0.34 to 1.02); p = 0.057) or biopsy-proven subclinical [HR (95% CI): 1.49 (0.76 to 2.92); p = 0.249] ACR, respectively. Combined events [HR (95% CI): 0.85 (0.56 to 1.29); p = 0.438], patient and graft survival, delayed graft function (DGF), 3-year glomerular filtration rate (GFR) [53.8 (40.6;65.7) versus 49.8 (36.8;62.5) mL/min/1.73 m2, p = 0.50], and adverse events (AEs) were not significantly different between groups. Chronicity scores other than CAN predict long-term graft outcome. Study limitations include small sample size and unblinded design. Conclusions In this study, we found that in deceased donor kidney transplant recipients on low-dose CsA and no steroids, MMF had no significant benefits over AZA. This finding suggests that AZA, due to its lower costs, could safely replace MMF in combination with minimized immunosuppression. Trial registration ClinicalTrials.gov NCT00494741; EUDRACT 2006-005604-14.

Utility and safety of early allograft biopsy in adult deceased donor kidney transplant recipients

2019 ◽  
Vol 24 (4) ◽  
pp. 356-368 ◽  
Author(s):  
Evaldo Favi ◽  
Ajith James ◽  
Carmelo Puliatti ◽  
Phil Whatling ◽  
Mariano Ferraresso ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Deceased Donor ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Donor Kidney ◽  
Allograft Biopsy ◽  
Deceased Donor Kidney ◽  
Deceased Donor Kidney Transplant

Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies

2018 ◽  
Vol 46 ◽  
pp. 8-13 ◽  
Author(s):  
Xicohténcatl Ixtlapale-Carmona ◽  
Adriana Arvizu ◽  
Adrian De-Santiago ◽  
Norma González-Tableros ◽  
Mayra López ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Deceased Donor ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Donor Kidney ◽  
Specific Antibodies ◽  
Deceased Donor Kidney ◽  
Donor Specific Antibodies ◽  
Deceased Donor Kidney Transplant

Difference in quality of life, fatigue and societal participation between living and deceased donor kidney transplant recipients

2013 ◽  
Vol 27 (4) ◽  
pp. E415-E423 ◽  
Author(s):  
Ingrid B. de Groot ◽  
J. Iraida E. Veen ◽  
Paul J. M. van der Boog ◽  
Sandra van Dijk ◽  
Anne M. Stiggelbout ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Kidney Transplant ◽  
Deceased Donor ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Donor Kidney ◽  
Deceased Donor Kidney ◽  
Societal Participation ◽  
Deceased Donor Kidney Transplant
Sign in / Sign up

Export Citation Format

Share Document